This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Martin Steegmaier, Ph.D.
Senior Vice President and Head of Research at MorphoSys


Martin earned his Ph.D. in biochemistry from the University of Basel, Swit­zerland studying molecular mechanism of inflammation at the Max-Planck- Institute for Immunology in Freiburg, Germany. In addition, Martin received an MBA from the Edinburgh Business School (UK). Before joining the pharma­ceutical industry, he spent 4 years as a postdoctoral fellow in the laboratory of Prof. Richard Scheller at Stanford University Medical School.

In 2000, Martin joined Boehringer Ingelheim’s Oncology Drug Discovery Department and held positions with increasing responsibility advancing first-in-class oncology projects into the clinic.

Martin joined Roche in 2006 in Basel and held various positions in Pharma Partnering and in the Oncology disease area. In 2012, Martin became the Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center Munich and together with his team he advanced novel proprietary antibody formats such as the CrossMab or the DutaFab bispecific formats.

In March 2020, Martin became Head of Research at MorphoSys, a fully integrated commercial-stage biopharmaceutical company headquartered in Planegg Munich, Germany (FSE & NASDAQ: MOR). MorphoSys is applying new cutting-edge technologies with the aim of generating differentiated, more efficacious, and safer antibody-based therapeutics in immuno-oncology and autoimmunity.

Agenda Sessions

  • Tafasitamab (MOR208): A Novel Fc-domain-engineered CD19-directed Monoclonal Antibody for the Treatment of B-cell Malignancies